Cannabis Sleep Benefits May Hinge on CBD and CBN Over THC

A new systematic review and meta-analysis has challenged one of the most durable assumptions in the cannabis sleep market: that THC is the cannabinoid doing the work. The University of South Florida College of Nursing team behind the paper found the most consistent evidence for better sleep tied to cannabidiol (CBD) and cannabinol (CBN), rather than delta-9-THC, the intoxicating compound most dispensary sleep products are built around.

The study¹, published in the Journal of the American Association of Nurse Practitioners on May 29, 2026, pooled trials testing cannabinoids against placebo in adults with insomnia. One of its co-authors, USF associate professor Andrea Efre, laid out the takeaway in an accompanying op-ed: the strongest signal came from CBD, CBN, and combinations of the two, while THC-containing formulations, in the paper’s words, “did not show significant improvement in sleep and had higher reports of adverse effects.”

That framing inverts how the market actually sells sleep. Most cannabis users say the plant improves their sleep, and the products marketed to them lean heavily on THC’s sedating reputation. Insomnia affects more than a third of adults, the authors note, and many turn to cannabis after running out of patience with behavioral therapy or conventional sleep drugs. The new analysis suggests the THC reputation may be running ahead of the evidence.

What the analysis actually found

This is a screen-and-pool review, not a single large trial. According to Efre’s op-ed, the team screened roughly 4,600 records, kept 18 that met its inclusion criteria, and carried seven into the quantitative meta-analysis. The included studies tested oral capsules, oils, and sublingual preparations, not smoked or vaporized cannabis, which limits how far the findings stretch to a typical dispensary flower purchase.

The dose detail is where the paper gets specific. CBD at 50 to 300 milligrams and CBN at 20 to 100 milligrams were associated with the most reliable improvements in sleep quality and duration. CBD below 50 milligrams generally did little on its own, helping only when paired with CBN. Across formulations, the pooled result pointed to less sleep disturbance, more total sleep time, and less daytime sleepiness, with side effects reported as mild to moderate: drowsiness, dry mouth, dizziness, and stomach upset.

The practice recommendation is unusually blunt for a research paper. The authors advise clinicians to counsel patients self-treating for sleep to avoid THC and to start low, with CBN alone or a CBN/CBD combination.

A field that hasn’t settled

One caveat carries real weight here: this is a single meta-analysis built on a small, uneven evidence base, and it does not match every recent attempt to answer the same question.

A separate meta-analysis published in Sleep Medicine Reviews in late 2025 reached a nearly opposite conclusion on CBD. That review, by a Brazilian team, pooled six randomized controlled trials covering 1,077 patients and found that cannabinoids improved self-reported sleep quality overall, but the benefit was driven by formulations that were not CBD-only. CBD by itself showed no statistically significant effect, while non-CBD cannabinoids, a category that includes THC and CBN, did.

Both reviews flag the same underlying problem. The trials are few, small, and statistically heterogeneous, and the scatter is wide enough that two competent teams can weight roughly the same literature and land in different places. The Sleep Medicine Reviews authors also noted that subjective sleep improvements often did not show up on objective measures like actigraphy, a recurring gap in cannabinoid sleep research. CBN, the “sleepy cannabinoid” of marketing copy, still rests largely on animal data and a handful of small human studies; its pro-sleep reputation has outpaced controlled evidence for years.

The one point of genuine agreement is narrower than either headline suggests: across both reviews, the simple story that THC is the sleep cannabinoid does not hold up cleanly, and CBN keeps surfacing as a compound that has earned a proper trial.

What it means for consumers

For shoppers, the practical mismatch is the most useful finding. Many commercial CBD sleep products carry doses well below the 50-to-300-milligram range where this review saw a signal, meaning a low-dose gummy marketed for sleep may sit beneath the threshold the evidence actually supports.

Dosing and formulation also carry a safety dimension that wellness marketing tends to skip. Efre noted that cannabinoids can interact with prescription drugs and shift their blood levels, and that people on blood thinners, cardiovascular drugs, or psychiatric medications should talk with a clinician before adding cannabinoid products. How CBD interacts with the body’s sleep and circadian systems remains an active research question, not a solved one.

What the field needs next is what both teams asked for: larger, longer trials using standardized formulations and doses, with objective sleep measurement rather than self-report alone. Until then, the most defensible reading is the modest one. The evidence points away from THC as the default sleep cannabinoid, and toward CBN and CBD as the compounds worth a closer look.

References:

^{1. Begazo, Katrina; Laing, Karen; Mineo, Angela; Efre, Andrea; Hanson, Ardis; Chan, Janet; Wofford, Kenneth. “Medical cannabis for treatment of insomnia in adults: A systematic review and meta-analysis” (2026). Journal of the American Association of Nurse Practitioners.}